Concepedia

Everolimus Interactions

Everolimus Interactions is a pharmacological construct that denotes the specific modulation of everolimus pharmacokinetics and pharmacodynamics through comorbid drug administration, characterized by its susceptibility to cytochrome P450 3A4 and P-glycoprotein-mediated interactions within transplant immunosuppressive regimens.

42

Publications

1.8K

Citations

332

Authors

125

Institutions

Publications per year

2017–2026

11

Variants

Everolimus Drug Interactions

Parents

Publications

42

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)

Dieter Koeberle, Jean‐François Dufour, Gyula Demeter et al. · Annals of Oncology · 2016 · 139 citations · Full text

, , +15

Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors

Nicola Fazio, Ashley Grossman, Stephen Saletan et al. · CHEST Journal · 2013 · 124 citations

, , +14

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

Marianne Pavel, Éric Baudin, Kjell E. Öberg et al. · Annals of Oncology · 2017 · 120 citations · Full text

, , +17

Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours

M. Campone, Vincent Lévy, Emmanuelle Bourbouloux et al. · British Journal of Cancer · 2009 · 97 citations · Full text

, , +17

Differential Influence of Two Cyclosporine Formulations on Everolimus Pharmacokinetics: A Clinically Relevant Pharmacokinetic Interaction

John M. Kovarik, Jyoti Kalbag, Joaquim Figueiredo et al. · The Journal of Clinical Pharmacology · 2002 · 87 citations

, , +16

1–5 of 42

Authors

332

  1. JM
    John M. Kovarik

    Novartis (Switzerland), Switzerland

    4 publications · 247 citations

    4

    h-index

  2. GJ
    Gerald J. Fetterly

    Roswell Park Comprehensive Cancer Center, United States

    2 publications · 44 citations

    2

    h-index

  3. SW
    Sun Woo Lim

    Catholic University of Korea, South Korea

    2 publications · 71 citations

    2

    h-index

  4. DB
    D. Beyer

    Novartis (Switzerland), Switzerland

    2 publications · 111 citations

    2

    h-index

  5. CR
    Christiane Rordorf

    Novartis (Switzerland), Switzerland

    2 publications · 136 citations

    2

    h-index

1–5 of 332

Institutions

125

  1. Novartis (Switzerland)

    Basel, Switzerland

    9 h-index

    34 publications

    2.5K citations

  2. Charité - Universitätsmedizin Berlin

    Berlin, Germany

    3 h-index

    13 publications

    447 citations

  3. The Catholic University of Korea Seoul St. Mary's Hospital

    Seoul, South Korea

    3 h-index

    14 publications

    513 citations

  4. Catholic University of Korea

    Seoul, South Korea

    3 h-index

    13 publications

    485 citations

  5. Medizinische Hochschule Hannover

    Hanover, Germany

    3 h-index

    17 publications

    352 citations

  6. University of Pavia

    Pavia, Italy

    2 h-index

    3 publications

    86 citations

  7. University at Buffalo, State University of New York

    Buffalo, United States

    2 h-index

    6 publications

    132 citations

  8. University of California, San Francisco

    San Francisco, United States

    2 h-index

    4 publications

    234 citations

1–8 of 125

Venues

  1. The Journal of Clinical Pharmacology

    3 publications · 149 citations

    3

    h-index

  2. Transplantation

    3 publications · 122 citations

    3

    h-index

  3. Annals of Oncology

    2 publications · 259 citations

    2

    h-index

  4. British Journal of Pharmacology

    BJP · 2 publications · 100 citations

    2

    h-index

  5. British Journal of Clinical Pharmacology

    BJCP · 1 publications · 54 citations

    1

    h-index

1–5